Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
A new oral drug from AstraZeneca is heading into large-scale clinical trials. Elecoglipron, a once-daily pill, mimics a natural gut hormone. Researchers are calling its early results clinically meaningful. The drug achieved over 11% average body weight loss in people with obesity at 36 weeks. It also delivered significant blood sugar improvements in people with type 2 diabetes.
Two Phase IIb trials, VISTA and SOLSTICE, generated these findings. Researchers presented the data at the American Diabetes Association’s 2026 Scientific Sessions. The Lancet published both studies simultaneously.
Elecoglipron belongs to the same drug class as Ozempic and Wegovy. Doctors call this class GLP-1 receptor agonists. Unlike those injectable medications, elecoglipron comes as a tablet. Patients take it once daily, with no food or fasting requirements. That distinction matters. Small molecule pills scale more easily in manufacturing than peptide-based injectables. Patients who prefer or require an oral option may also find it more accessible.
The VISTA trial enrolled 310 adults with obesity or overweight. All participants carried at least one related health condition. Those taking the 75mg dose lost an average of 10.5% of their body weight by week 26. By week 36, that figure reached 11.8%. The placebo group lost just 0.3%. Nearly 89% of participants on the top dose lost at least 5% of their body weight. Clinical guidelines widely use that threshold to define meaningful weight loss.
The drug also reduced blood pressure and C-reactive protein levels. C-reactive protein signals inflammation linked to cardiovascular risk. These findings came from exploratory analyses and need further confirmation. Still, they add to the broader picture of metabolic benefit.
The SOLSTICE trial focused on type 2 diabetes. It enrolled 404 adults with a mean baseline HbA1c of 7.9%. Participants on elecoglipron 75mg cut their HbA1c by an average of 1.9 percentage points at 26 weeks. The placebo group achieved only 0.2%. Nine out of ten participants on the highest dose reached an HbA1c below 7%. Another 85% reached 6.5% or lower. Diabetes management guidelines recommend both as standard targets.
The same group also lost an average of 7.7% of their body weight. The placebo group lost 1.7%. For a diabetes drug, that dual effect stands out. Obesity and type 2 diabetes share strong biological links, and treatments that target both carry clear clinical value.
Side effects followed the typical GLP-1 pattern. Patients most commonly reported nausea, constipation, diarrhea, and vomiting. Most cases were mild to moderate. A few patients stopped treatment because of side effects. Neither trial detected liver safety signals. Low blood sugar episodes in the diabetes trial were uncommon.
AstraZeneca says the Phase II tolerability data directly shaped the dose escalation schedule for Phase III. The company structured the ramp-up period to help patients adjust more comfortably before reaching the full dose.
The Phase III programme runs on two fronts. The EMBOLD trials will test elecoglipron in people with obesity or overweight, both with and without diabetes. The ELUMINATE trials will assess it alone and in combination with dapagliflozin, an established diabetes and kidney medication. The company also plans separate trials focused on long-term cardiovascular and kidney outcomes.
The scale of the problem adds urgency to this research. Close to three billion people worldwide live with obesity or overweight. Obesity is connected to more than 200 health complications. Nearly 90% of people newly diagnosed with type 2 diabetes also carry excess weight. By 2045, experts project global diabetes prevalence will reach 783 million people.
Effective oral options that tackle both conditions remain scarce. Injectable GLP-1 drugs currently dominate this space. If elecoglipron’s Phase III results hold, it could give clinicians and patients a viable pill-based alternative.
